Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.
The surging popularity of bitcoin has some brand-name venture capitalists investing real money in the controversial virtual currency. Just since
Author : laragon
TPG has had much luck tapping the IPO market during the past 12 months. The PE firm’s most recent success
Author : lbeltran
This week marks the one-year anniversary of Facebook’s public offering, one of the most highly anticipated market events in Wall
Author : connieloizos
Blackstone Group LP is planning to create a hedge fund which will consist of the boldest trades from the third-party
Author : reuters-news
Shares of Tableau Software soared nearly 64% on Friday, promising a massive return for its venture capital backers New Enterprise
Author : lbeltran
Welcome! Join the peHUB community to make connections, share your opinion, and follow your favorite authors. It's quick and easy.
Click here to get started!
ACTIVE COMMUNITY MEMBERS
Aspen Aerogels, Inc. said it raised $22.5 million in a convertible note financing and has decided not to pursue an initial public offering. The company said it will withdraw its S-1 registration statement.The new […]
sister magazine Buyouts is reporting the two biggest NY State pensions are both expanding their private equity staffs
Yesterday, Tableau raised $254.2 […]
active 2 days, 8 hours ago
active 3 weeks, 4 days ago
active 3 weeks, 5 days ago